Single-center experience with the thoratec ventricular assist device

Körfer, Reiner; El‐Banayosy, Aly; Arusoglu, Latif; Minami, Kazutomo; Körner, Michael; Kizner, L.; Fey, O.; Schütt, U.; Morshuis, Michiel; Posival, Herbert

doi:10.1016/s0022-5223(00)70142-5

Cited by 84 publications

(36 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relatively older age of these patients (range 11-20 years) and larger size (body surface area range 1.4 -2.2 m 2 ) allowed the use of this device. As in the adult experience, the majority of children supported by the vented electric model were discharged home with resumption of normal activities (McBride et al, 1999;Korfer at al., 2000). A number of reports exist describing experience with the Thoratec VAD (Thoratec Corp., Pleasanton, CA) in children.…”

Section: Heartmate Thoratec and The Abiomed Bvs 5000mentioning

confidence: 97%

Ventricular Assist Devices for Pediatric Heart Disease

Yıldız¹

2011

New Aspects of Ventricular Assist Devices

View full text Add to dashboard Cite

Section: Heartmate Thoratec and The Abiomed Bvs 5000mentioning

confidence: 97%

Ventricular Assist Devices for Pediatric Heart Disease

Yıldız¹

2011

New Aspects of Ventricular Assist Devices

View full text Add to dashboard Cite

“…The pump moves blood from the LV to aortic arch where it flows normally through the patient's arterial system. Short-term use of these devices in patients awaiting transplantation can maintain hemodynamics, improve vital organ function and exercise tolerance, allow patients to be discharged from the hospital, and provides them with a reasonable quality of life and a relatively low incidence of major adverse events (8)(9)(10)(11)(12)(13)(14)(15). Table 1 is showing a summary of some types of ventricular assist device.…”

Section: Ventricular Assist Devicesmentioning

confidence: 99%

Cardiac Compression Devices: Alternative Technology and Innovative Concept

Daliri

Yadollahi

Jadbabaei

2017

Multidiscip Cardio Annal

View full text Add to dashboard Cite

Heart failure is a leading cause of death around the world. Heart transplantation is the only reliable therapy for improving functional capacity, quality of life, life expectancy, and limiting the options for heart failure patients. In fact, a large number of patients with severe heart failure in need of heart transplantation are unable to receive therapy with up to 30% mortality before a heart is donated. In recent decades, cardiac replacement and assisting therapies have presented promising outcomes to treat these end-stage patients as alternative solutions. These devices are capable of providing temporary to permanent, partial or full assistance. Such devices can be divided into two categories based on location and mechanism of augmentation: 1) devices exposed directly to blood including ventricular assistive devices (VADs) and total artificial hearts (TAHs) and 2) devices that augment cardiac output through compression of ventricles or another part of circulatory system with no direct contact to blood such as extra-cardiac compression devices (ECCDs). In recent years, novel ECCDs which compress tissue and muscles to indirectly assist blood pumping have been developed to circumscribe problems associated with blood-contacting devices and the risks involved with piercing arterial and ventricular walls. Not only do ECCDs aim to reduce risks from the patient and surgeon perspective, the complexity of engineering an intra-corporeal extra-cardiac device is also reduced.

show abstract

“…Since the late 1980 s, extracorporeal pulsatile VADs have been widely applicable for BTT, [23][24][25] and in the early 1990 s implantable pulsatile VADs were available in the US. 26-28 Among them, popular devices were the extracorporeal Thoratec PVAD 23-25 and the implantable HeartMate I.…”

Section: Continuous Flow Pumpsmentioning

confidence: 99%